Malaria is a leading cause of mortality and morbidity globally, and effective vaccines are
urgently needed. Malaria vaccine approaches can be broadly grouped as pre‐erythrocytic …

Dedicated to the memory of Professors Henry G. Kunkel and Bruce Merrifield (Rockefeller
University, New York), who introduced us to the fascinating worlds of immunology and …

Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting
results in different populations. We report a randomised double-blind trial of the SPf66 …

Preclinical and clinical studies have established the safety and immunogenicity of the
chemically synthesised SPf66 malaria vaccine. The present study is a phase III randomised …

SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-
erythrocytic and asexual blood-stage proteins of Plasmodium falciparum. SPf66 was found …

Adverse events following immunization (AEFI) are not uncommon, with injection site
reactions (ISRs) being the most common. Predictors of injection site reactions are vaccine …

SPf66 is a synthetic malaria peptide vaccine, which has been widely tested in combination
with aluminium hydroxide (alum) as the adjuvant. Since this formulation is weakly …

Interest in vaccine adjuvants is intense and growing, because many of the new subunit
vaccine candidates lack sufficient immunogenicity to be clinically useful. In this review, I …

Combining key antigens from the different stages of the P. falciparum life cycle in the context
of a multi-stage-specific cocktail offers a promising approach towards the development of a …

Introduction Malaria represents a public health challenge in tropical and subtropical regions,
and currently deployed control strategies are likely insufficient to drive elimination of malaria …